The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Allan Lipton

Division of Hematology/Oncology

Room C-6830

College of Medicine

Penn State University

USA

[email]@psu.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Division of Hematology/Oncology, Room C-6830, College of Medicine, Penn State University, USA. 2011
  • Pennsylvania State University Milton S Hershey Medical Center, Hershey, USA. 2002 - 2011
  • Penn State Hershey Cancer Institute, Hematology-Oncology, Penn State/Hershey Medical Center, Hershey, Pennsylvania. 2011
  • Division of Hematology/Oncology, Milton S. Hershey Medical Center, Pennsylvania State University Cancer Institute, Room C6830, USA. 2010
  • Department of Medicine, The Milton S. Hershey Medical Center, Hershey, Pennsylvania 17033, USA. 2008 - 2010
  • The Milton S. Hershey Medical Center/Pennsylvania State University College of Medicine, Hershey, USA. 2003 - 2010
  • Division of Hematology-Oncology, Penn State/Hershey Medical Center, Hershey, USA. 2006 - 2010

References

  1. Zoledronic acid: multiplicity of use across the cancer continuum. Lipton, A. Expert. Rev. Anticancer. Ther (2011) [Pubmed]
  2. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Lipton, A., Goessl, C. Bone (2011) [Pubmed]
  3. Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy. Lipton, A., Leitzel, K., Ali, S.M., Carney, W., Platek, G., Steplewski, K., Westlund, R., Gagnon, R., Martin, A.M., Maltzman, J. Cancer (2011) [Pubmed]
  4. Should bisphosphonates be utilized in the adjuvant setting for breast cancer? Lipton, A. Breast Cancer Res. Treat. (2010) [Pubmed]
  5. Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastases. Lipton, A., Campbell-Baird, C., Harvey, H., Kim, C., Demers, L., Costa, L. Am. J. Clin. Oncol. (2010) [Pubmed]
  6. Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. Lipton, A., Campbell-Baird, C., Witters, L., Harvey, H., Ali, S. J. Clin. Gastroenterol. (2010) [Pubmed]
  7. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. Lipton, A., Köstler, W.J., Leitzel, K., Ali, S.M., Sperinde, J., Weidler, J., Paquet, A., Sherwood, T., Huang, W., Bates, M. Cancer (2010) [Pubmed]
  8. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Lipton, A., Cook, R., Saad, F., Major, P., Garnero, P., Terpos, E., Brown, J.E., Coleman, R.E. Cancer (2008) [Pubmed]
  9. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Lipton, A., Steger, G.G., Figueroa, J., Alvarado, C., Solal-Celigny, P., Body, J.J., de Boer, R., Berardi, R., Gascon, P., Tonkin, K.S., Coleman, R.E., Paterson, A.H., Gao, G.M., Kinsey, A.C., Peterson, M.C., Jun, S. Clin. Cancer Res. (2008) [Pubmed]
  10. Emerging role of bisphosphonates in the clinic--antitumor activity and prevention of metastasis to bone. Lipton, A. Cancer Treat. Rev. (2008) [Pubmed]
  11. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer. Lipton, A., Leitzel, K., Chaudri-Ross, H.A., Evans, D.B., Ali, S.M., Demers, L., Hamer, P., Brown-Shimer, S., Pierce, K., Gaur, V., Carney, W. J. Clin. Oncol. (2008) [Pubmed]
  12. RANKL inhibition in the treatment of bone metastases. Lipton, A., Jun, S. Current. Opinion. Supportive. Palliative. Care (2008) [Pubmed]
  13. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Lipton, A., Cook, R.J., Major, P., Smith, M.R., Coleman, R.E. Oncologist (2007) [Pubmed]
  14. The safety of zoledronic acid. Lipton, A. Expert. Opin. Drug. Saf (2007) [Pubmed]
  15. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. Lipton, A., Steger, G.G., Figueroa, J., Alvarado, C., Solal-Celigny, P., Body, J.J., de Boer, R., Berardi, R., Gascon, P., Tonkin, K.S., Coleman, R., Paterson, A.H., Peterson, M.C., Fan, M., Kinsey, A., Jun, S. J. Clin. Oncol. (2007) [Pubmed]
  16. Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. Lipton, A., Cook, R.J., Coleman, R.E., Smith, M.R., Major, P., Terpos, E., Berenson, J.R. Clin. Lymphoma. Myeloma (2007) [Pubmed]
  17. Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer. Lipton, A. Clin. Breast Cancer (2007) [Pubmed]
  18. Managing aromatase inhibitor-associated bone loss in breast cancer. Lipton, A., Gnant, M., Aapro, M. Women's. Health. (london,. England) (2007) [Pubmed]
  19. Biochemical bone markers in breast cancer. Lipton, A. Cancer Treat. Rev. (2006) [Pubmed]
  20. Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference. Lipton, A., Berenson, J.R., Body, J.J., Boyce, B.F., Bruland, O.S., Carducci, M.A., Cleeland, C.S., Clohisy, D.R., Coleman, R.E., Cook, R.J., Guise, T.A., Pearse, R.N., Powles, T.J., Rogers, M.J., Roodman, G.D., Smith, M.R., Suva, L.J., Vessella, R.L., Weilbaecher, K.N., King, L. Clin. Cancer Res. (2006) [Pubmed]
  21. Future treatment of bone metastases. Lipton, A. Clin. Cancer Res. (2006) [Pubmed]
  22. Management of bone metastases in breast cancer. Lipton, A. Curr. Treat. Options. Oncol (2005) [Pubmed]
  23. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Lipton, A., Leitzel, K., Ali, S.M., Demers, L., Harvey, H.A., Chaudri-Ross, H.A., Evans, D., Lang, R., Hackl, W., Hamer, P., Carney, W. Cancer (2005) [Pubmed]
  24. New therapeutic agents for the treatment of bone diseases. Lipton, A. Expert. Opin. Biol. Ther (2005) [Pubmed]
  25. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. Lipton, A. J. Support. Oncol (2004) [Pubmed]
  26. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Lipton, A., Colombo-Berra, A., Bukowski, R.M., Rosen, L., Zheng, M., Urbanowitz, G. Clin. Cancer Res. (2004) [Pubmed]
  27. Toward new horizons: the future of bisphosphonate therapy. Lipton, A. Oncologist (2004) [Pubmed]
  28. Gemcitabine/Irinotecan/celecoxib in pancreatic cancer. Lipton, A., Harvey, H., Witters, L., Kerr, S., Legore, K., Campbell, C. Oncology (Williston Park, N.Y.) (2004) [Pubmed]
  29. Bisphosphonates and metastatic breast carcinoma. Lipton, A. Cancer (2003) [Pubmed]
  30. Bone metastases in breast cancer. Lipton, A. Curr. Treat. Options. Oncol (2003) [Pubmed]
  31. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. Lipton, A., Ali, S.M., Leitzel, K., Demers, L., Harvey, H.A., Chaudri-Ross, H.A., Brady, C., Wyld, P., Carney, W. J. Clin. Oncol. (2003) [Pubmed]
  32. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Lipton, A., Zheng, M., Seaman, J. Cancer (2003) [Pubmed]
  33. Bisphosphonate therapy in the oncology setting. Lipton, A. Expert. Opin. Emerg. Drugs (2003) [Pubmed]
  34. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. Lipton, A., Ali, S.M., Leitzel, K., Demers, L., Chinchilli, V., Engle, L., Harvey, H.A., Brady, C., Nalin, C.M., Dugan, M., Carney, W., Allard, J. J. Clin. Oncol. (2002) [Pubmed]
  35. Serum osteoprotegerin levels in healthy controls and cancer patients. Lipton, A., Ali, S.M., Leitzel, K., Chinchilli, V., Witters, L., Engle, L., Holloway, D., Bekker, P., Dunstan, C.R. Clin. Cancer Res. (2002) [Pubmed]
  36. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Lipton, A., Small, E., Saad, F., Gleason, D., Gordon, D., Smith, M., Rosen, L., Kowalski, M.O., Reitsma, D., Seaman, J. Cancer Invest. (2002) [Pubmed]
 
WikiGenes - Universities